Resmetirom for nonalcoholic steatohepatitis.
作者信息
Fahim Shahariar Mohammed, Tice Jeffrey A, Suh Kangho, Carlson Josh J, Richardson Marina, Chu Janet N, Herce-Hagiwara Belen, Agboola Foluso, Rind David, Pearson Steven D
机构信息
Institute for Clinical and Economic Review, Boston, MA.
Division of General Internal Medicine, University of California San Francisco.
出版信息
J Manag Care Spec Pharm. 2023 Oct;29(10):1169-1172. doi: 10.18553/jmcp.2023.29.10.1169.
Abstract
摘要
相似文献
1
Resmetirom for nonalcoholic steatohepatitis.用于非酒精性脂肪性肝炎的瑞美替隆
J Manag Care Spec Pharm. 2023 Oct;29(10):1169-1172. doi: 10.18553/jmcp.2023.29.10.1169.
2
Early Cost-Effectiveness and Price Threshold Analyses of Resmetirom: An Investigational Treatment for Management of Nonalcoholic Steatohepatitis.瑞美替隆的早期成本效益和价格阈值分析：一种用于治疗非酒精性脂肪性肝炎的研究性疗法
Pharmacoecon Open. 2023 Jan;7(1):93-110. doi: 10.1007/s41669-022-00370-2. Epub 2022 Sep 14.
3
Hepatic Fat Reduction Due to Resmetirom in Patients With Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life.非酒精性脂肪性肝炎患者使用瑞美替隆后肝脏脂肪减少与生活质量改善相关。
Clin Gastroenterol Hepatol. 2022 Jun;20(6):1354-1361.e7. doi: 10.1016/j.cgh.2021.07.039. Epub 2021 Jul 27.
4
Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: rationale for the development of resmetirom (MGL-3196).甲状腺模拟物作为非酒精性脂肪性肝炎的新型治疗药物：resmetirom（MGL-3196）的研发原理
Expert Opin Investig Drugs. 2020 Feb;29(2):99-101. doi: 10.1080/13543784.2020.1708899. Epub 2019 Dec 25.
5
Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH.在一项为期 36 周的 NASH 患者 2 期活性治疗延伸研究中，Resmetirom 对非侵入性终点的影响。
Hepatol Commun. 2021 Jan 4;5(4):573-588. doi: 10.1002/hep4.1657. eCollection 2021 Apr.
6
Resmetirom: An Orally Administered, Smallmolecule, Liver-directed, β-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis.瑞美替隆：一种口服的小分子、肝脏靶向、β 选择性甲状腺激素受体激动剂，用于治疗非酒精性脂肪性肝病和非酒精性脂肪性肝炎。
touchREV Endocrinol. 2023 May;19(1):60-70. doi: 10.17925/EE.2023.19.1.60. Epub 2023 May 1.
7
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.Resmetirom（MGL-3196）治疗非酒精性脂肪性肝炎：一项多中心、随机、双盲、安慰剂对照的 2 期临床试验。
Lancet. 2019 Nov 30;394(10213):2012-2024. doi: 10.1016/S0140-6736(19)32517-6. Epub 2019 Nov 11.
8
Update on Clinical Trials for Nonalcoholic Steatohepatitis.非酒精性脂肪性肝炎临床试验的最新进展
Gastroenterol Hepatol (N Y). 2023 Jul;19(7):371-381.
9
Prof Jörn Schattenberg sheds light on key treatment and diagnostic approaches to nonalcoholic steatohepatitis (NASH).约恩·沙滕贝格教授阐述了非酒精性脂肪性肝炎（NASH）的关键治疗和诊断方法。
Expert Opin Investig Drugs. 2020 Feb;29(2):111-113. doi: 10.1080/13543784.2020.1721150. Epub 2020 Feb 3.
10
Emerging therapies for the treatment of nonalcoholic steatohepatitis: A systematic review.新兴疗法治疗非酒精性脂肪性肝炎：系统评价。
Pharmacotherapy. 2021 Mar;41(3):315-328. doi: 10.1002/phar.2489. Epub 2021 Feb 17.
引用本文的文献
1
Value-Based Pricing of Resmetirom for Metabolic Dysfunction-Associated Steatotic Liver Disease.用于代谢功能障碍相关脂肪性肝病的resmetirom的基于价值的定价。
JAMA Netw Open. 2025 Jun 2;8(6):e2517122. doi: 10.1001/jamanetworkopen.2025.17122.
2
Unveiling Resmetirom: A systematic review and meta-analysis on its impact on liver function and safety in non-alcoholic steatohepatitis treatment.揭开瑞美替隆的面纱：关于其在非酒精性脂肪性肝炎治疗中对肝功能和安全性影响的系统评价与荟萃分析
JGH Open. 2024 Oct 1;8(10):e70025. doi: 10.1002/jgh3.70025. eCollection 2024 Oct.
3
Metabolic Dysfunction-associated Steatohepatitis and Cardiovascular Disease Prevention - Is Resmetirom Useful?代谢功能障碍相关脂肪性肝炎与心血管疾病预防——瑞美替昂有用吗？
Curr Vasc Pharmacol. 2025;23(1):4-7. doi: 10.2174/0115701611340703240809044916.
本文引用的文献
1
Early Cost-Effectiveness and Price Threshold Analyses of Resmetirom: An Investigational Treatment for Management of Nonalcoholic Steatohepatitis.瑞美替隆的早期成本效益和价格阈值分析：一种用于治疗非酒精性脂肪性肝炎的研究性疗法
Pharmacoecon Open. 2023 Jan;7(1):93-110. doi: 10.1007/s41669-022-00370-2. Epub 2022 Sep 14.
2
Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis.药物治疗非酒精性脂肪性肝炎试验中安慰剂反应的发生率和相关因素：系统评价和荟萃分析。
Clin Gastroenterol Hepatol. 2019 Mar;17(4):616-629.e26. doi: 10.1016/j.cgh.2018.06.011. Epub 2018 Jun 18.
3
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.非酒精性脂肪性肝病的诊断与管理：美国肝病研究协会的实践指南
Hepatology. 2018 Jan;67(1):328-357. doi: 10.1002/hep.29367. Epub 2017 Sep 29.
4
Contribution of Alcoholic and Nonalcoholic Fatty Liver Disease to the Burden of Liver-Related Morbidity and Mortality.酒精性和非酒精性脂肪性肝病对肝脏相关发病率和死亡率负担的贡献。
Gastroenterology. 2016 Jun;150(8):1778-85. doi: 10.1053/j.gastro.2016.03.005. Epub 2016 Mar 12.
5
Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.非酒精性脂肪肝与非酒精性脂肪性肝炎的纤维化进展：配对活检研究的系统评价和荟萃分析
Clin Gastroenterol Hepatol. 2015 Apr;13(4):643-54.e1-9; quiz e39-40. doi: 10.1016/j.cgh.2014.04.014. Epub 2014 Apr 24.
Zotero 插件